Chief Executive Officer and Co-Founder of Raptor, commented, "As a clinical-stage company with multiple active programs, we are pleased to welcome Dr. Rioux. This is an ideal time for Patrice to join Raptor. We believe his successful clinical and regulatory track record will serve us well as we prepare for a pivotal clinical trial in our lead clinical program, DR Cysteamine in cystinosis, and position us to advance our other clinical-stage programs through the clinic and into the market."
Dr. Rioux said, "I am excited to join the team at Raptor, as I believe in the potential of the Company's pipeline of clinical-stage drug candidates that address some serious unmet medical needs."
Status of Raptor's Clinical-Stage Development Programs
Under Dr. Rioux' guidance, the Company expects to conduct its pivotal clinical study for DR Cysteamine in cystinosis in the second half of 2009 and file an NDA in 2010.
In February, 2009, Raptor announced the completion of patient enrollment in its Phase 2a open-label clinical trial to evaluate a prototype formulation of DR Cysteamine in juvenile patients diagnosed with NASH. Results from that study are expected later this year.
In November, 2008, Raptor entered into an agreement with the Centre Hospitalier Universitaire d'Angers ("CHU d'Angers") of France to evaluate DR Cysteamine in a two-year, multi-center Phase II clinical trial in Huntington's, sponsored by CHU d'Angers and supported by a grant from the Programme Hospitalier de Recherche Clinique - National, a program under the French Ministry of Health. Initiation of the Phase II Huntington's study, in which Raptor will supply the study drug, is planned for late 2009.
Also in November 2008, Raptor announced results of its Phase 2a study of Convivia in 32 ALDH2-deficient subjects of Japanese descent. The Company is actively exploring partnering opportunities for Convi
'/>"/>
SOURCE Raptor Pharmaceuticals Corp. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 Related medicine technology :1.
Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)2.
Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program3.
Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease4.
Raptor Pharmaceuticals Provides Update on Targeting Platforms5.
Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)6.
Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease7.
Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)8.
Raptor Pharmaceuticals Provides Update of Product Programs9.
Strativa Pharmaceuticals Provides Product Pipeline Update10.
Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 200911.
Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results